1-5 of 5
James C. Wade, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.

Brenda M. Sandmaier, MD, Michael Maris, MD, Barry Storer, PhD, Lars Vindelov, MD, Amelia Langston, MD, James C. Wade, MD, MPH, Wolfgang A. Bethge, MD, Michael Pulsipher, MD, Thoralf Lange, MD, Thomas Chauncey, MD, Finn Petersen, MD, Kai Hübel, MD, Ann Woolfrey, MD, Mary E.D. Flowers, MD, David G. Maloney, MD, PhD, Rainer F. Storb, MD
Journal: Blood
Blood (2009) 114 (22): 348.
https://doi.org/10.1182/blood.V114.22.348.348
Published: 2009
Journal Articles

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, MD, MS, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Thomas Chauncey, MD, Richard T. Maziarz, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Dietger Niederwieser, MD, Edward Agura, MD, James C. Wade, MD, MPH, Amelia A Langston, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2147.
https://doi.org/10.1182/blood.V112.11.2147.2147
Published: 2008
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, David G. Maloney, MD, PhD, Georg Franke, MD, Judith Shizuru, MD, PhD, Thomas Chauncey, MD, Edward Agura, MD, Richard T. Maziarz, MD, Firoozeh Sahebi, MD, Amelia A Langston, MD, James C. Wade, MD, MPH, Michael Maris, MD, Benedetto Bruno, MD, Andrew M. Yeager, MD, Michael Pulsipher, MD, Finn Petersen, MD, Wolfgang A. Bethge, MD, Peter A. McSweeney, MD, Dietger Niederwieser, MD, Karl G. Blume, MD, Rainer F. Storb, MD
Journal: Blood
Blood (2008) 112 (11): 2162.
https://doi.org/10.1182/blood.V112.11.2162.2162
Published: 2008
Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Andrew R. Rezvani, MD, L. Norasetthada, MD, T. Gooley, PhD, Mohamed Sorror, MD, Stephen J. Forman, MD, Edward Agura, MD, T. Chauncey, MD, PhD, Richard T. Maziarz, MD, Michael Maris, MD, J. Shizuru, MD, PhD, B. Bruno, MD, James C. Wade, MD, T. Lange, MD, Andrew Yeager, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3037.
https://doi.org/10.1182/blood.V110.11.3037.3037
Published: 2007
Journal Articles

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Andrew R. Rezvani, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael Maris, MD, Edward Agura, MD, Richard Maziarz, MD, James C. Wade, MD, Thomas Chauncey, MD, PhD, Stephen J. Forman, MD, Dietger W. Niederwieser, MD, Judith Shizuru, MD, Amelia Langston, MD, Michael Pulsipher, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 3124.
https://doi.org/10.1182/blood.V108.11.3124.3124
Published: 2006